Results 101 to 110 of about 46,872 (214)

IL RENE COME NUOVO TARGET DI DI FARMACI ANTIDIABETICI:INIBITORI DI SGLT2 [PDF]

, 2015
IL DIABETE DI TIPO 2 RAPPRESENTA UNA DELLE PATOLOGIE A PIù AMPIO E PROGRESSIVO INCREMENTO NELLA POPOLAZIONE MONDIALE. LA RICERCA DI NUOVI FARMACI E' PERTANTO UN'IMPELLENTE NECESSITA'.
SHTJEFNI, ELONA
core  

Computational Discovery of Novel SGLT2 Inhibitors from Eight Selected Medicine Food Homology Herbs Using a Multi-Stage Virtual Screening Pipeline

Pharmaceuticals
Background/Objectives: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are essential antidiabetic medications. However, their side effects warrant careful consideration.
Zeyu Chen, Kaiqi Tan, Yi Shi, Muchong Liu, Lang Yi, Tongxi Chen, Yunlong Bai   +6 more
doaj   +1 more source

Impact of sodium‒glucose cotransporter‐2 inhibitors in patients with recent versus previous myocardial infarction: a systematic review and meta-analysis

Cardiovascular Diabetology
Background Sodium‒glucose cotransporter 2 (SGLT2) inhibitors have been included in heart failure (HF) guidelines because of their benefits in reducing mortality and hospitalization rates. However, the timing and benefits of initiating SGLT2 inhibitors in
Pedro Gabriel Scardini, Eric Shih Katsuyama, Alonzo Armani Prata, Julia Marques Fernandes, Christian Ken Fukunaga, Wilson Falco Neto, Ana Carolina Covre Coan, Naieli Machado de Andrade, Abraão Santana Silva, Rafael Petri Pinheiro, Luciana Gioli Pereira, Remo H. M. Furtado   +11 more
doaj   +1 more source

The protective effect of sodium-glucose cotransporter 2 inhibitors and the incidence of ovarian cancer: a nationwide cohort preliminary study

Archives of Medical Science
Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are commonly used antihyperglycemic medications that also exhibit anti-inflammatory and antioxidant effects.
Ke-Hsin Ting, Jing-Yang Huang, Pei-Lun Liao, Chia-Yi Lee, Shun-Fa Yang   +4 more
doaj   +1 more source

Contemporary NSTEMI management: the role of the hospitalist. [PDF]

, 2019
Non-ST-segment elevation myocardial infarction (NSTEMI) is defined as elevated cardiac biomarkers of necrosis in the absence of persistent ST-segment elevation in the setting of anginal symptoms or other acute event.
Amin, Alpesh, Cohen, Marc, Deitelzweig, Steven, DiLascia, Christopher, Fanikos, John, Kaatz, Scott, Pollack, Charles V, Slattery, David, Tuder, Regan, Wang, Tracy   +9 more
core   +1 more source

SGLT2 inhibitor

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018
Akira Nishiyama, Hirofumi Hitomi, Daisuke Nakano   +2 more
openaire   +2 more sources

Ertugliflozin - SGLT2 inhibitor [PDF]

Interní medicína pro praxi, 2019
openaire   +1 more source

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure

Vascular Health and Risk Management, 2016
James W Reed Morehouse School of Medicine, Atlanta, GA, USA Abstract: SGLT2 inhibitors are glucose-lowering agents used to treat type 2 diabetes mellitus (T2DM).
Reed JW
doaj  

Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study

Cardiovascular Diabetology
Background Renin–angiotensin–aldosterone system (RAS) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors are key treatments for diabetic kidney disease.
Sangmo Hong, Kyungdo Han, Kyung-Soo Kim, Cheol-Young Park   +3 more
doaj   +1 more source

SGLT2 Inhibitor [PDF]

, 2020
openaire   +1 more source